UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020840
Receipt number R000023914
Scientific Title A multi-Center, prospective study for maintenance of remission after discontinuation of adalimumab therapy in ulcerative colitis patients
Date of disclosure of the study information 2016/02/02
Last modified on 2023/02/08 14:16:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multi-Center, prospective study for maintenance of remission after discontinuation of adalimumab therapy in ulcerative colitis patients

Acronym

ROSE Study

Scientific Title

A multi-Center, prospective study for maintenance of remission after discontinuation of adalimumab therapy in ulcerative colitis patients

Scientific Title:Acronym

ROSE Study

Region

Japan


Condition

Condition

ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the possibility of discontinuation of adalimumab therapy without relapse for a year in ulcerative patients with adalimumab-induced remission.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

rate of sustained remission after discontinuation of adalimumab therapy

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

discontinuation of adalimumab therapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patients with adalimumab-induced remission for more than 6 months
(1)Partial Mayo score is 2 points or less , with no individual subscore exceeding 1 point
(2)Negative CRP
2.Patients with informed consent for this study by document

Key exclusion criteria

1.Patients with serious infection (sepsis etc.)
2.Patients with active tuberculosis
3.Patients with a history of hypersensitivity to any of the ingredients of Humira
4.Patients with a current or past history of demyelinating diseases (multiple sclerosis, etc.)
5.Patients with congestive heart failure
6.Patients with pregnancy or desiring for pregnancy
7.Patients with history of colectomy
8.Patients without informed consent
9.Patients who are considered ineligible for this study by the principal investigator

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Toyokawa
Middle name
Last name Toyokawa

Organization

Fukuyama Medical Center

Division name

Department of Gastroenterology

Zip code

720-8520

Address

4-14-17 Okinogamicho, Fukuyama City, Hiroshima

TEL

084-922-0001

Email

toyotatu@kmail.plala.or.jp


Public contact

Name of contact person

1st name Tatsuya
Middle name
Last name Toyokawa

Organization

Fukuyama Medical Center

Division name

Department of Gastroenterology

Zip code

720-8520

Address

4-14-17 Okinogamicho, Fukuyama City, Hiroshima

TEL

084-922-0001

Homepage URL


Email

toyotatu@kmail.plala.or.jp


Sponsor or person

Institute

Fukuyama Medical Center

Institute

Department

Personal name



Funding Source

Organization

Fukuyama Medical Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

same as above

Address

same as above

Tel

same as above

Email

same as above


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 02 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2015 Year 11 Month 12 Day

Date of IRB

2018 Year 04 Month 12 Day

Anticipated trial start date

2016 Year 02 Month 02 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 02 Month 02 Day

Last modified on

2023 Year 02 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023914


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name